YM Bio. Com Shs Share Discussion Threads

[rambutan2] 27/9/2006 12:15

YM BioSciences Announces AeroLEF(TM) Phase IIb Interim Review

- Benefit observed compared with placebo; Clinical trial to continue as
planned -

MISSISSAUGA, ON, Sept. 27 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,
AIM:YMBA), a company engaged in the acquisition, development and
commercialization of oncology and acute care products, today announced that
its DELEX Therapeutics division has received the results of an interim
analysis on the first 67 patients from its randomized, placebo-controlled
Phase IIb trial (DLXLEF-AP4) of AeroLEF(TM) for the treatment of moderate to
severe acute pain in post-surgical patients. The data indicated that AeroLEF
provided benefit compared to placebo, however the difference between the
treatment arm and placebo arm had not yet achieved the significance level
predefined in the study protocol and therefore the study will continue as
planned to enroll the original target of 99 randomized patients.

"This preliminary review indicates that we should continue to advance the
AeroLEF phase IIb study to full enrollment," said David Allan, Chairman and
CEO of YM BioSciences. "We look forward to analyzing the full data set at the
completion of the study early next year."

AeroLEF(TM) is a unique, inhaled-delivery composition of free and
liposome encapsulated fentanyl, for the treatment of moderate to severe acute
pain, including cancer pain. The Phase IIb study consisted of two parts.
Part I was an open label trial of 21 patients to allow investigators to gain
familiarity with administration of the product. Part II is a randomized,
double-blinded, and placebo-controlled trial of 99 patients, and is designed
to evaluate the safety and efficacy of multiple doses of AeroLEF(TM) for
management of pain in post-surgical patients following elective orthopedic
surgeries. The primary endpoint for this study is the Summed Pain Relief plus
Pain Intensity Difference (SPRID) scores during the first four hours after the
start of the initial dose. Secondary endpoints include Time to Effective Pain
Relief, as well as six safety endpoints.

Preliminary results from the open label portion of the DLXLEF-AP4 trial
will be presented at the American Society of Anesthesiologists Annual Meeting,
McCormick Place, Chicago, IL, on October 17, 2006 at 9:00 a.m. Central.

[rambutan2] 26/9/2006 01:23

3:40 PM ET
Trading Day with Pat Bolland
Cuban Cancer Treatment
David Allen, CEO, YM Biosciences

Duration: 5 m 24 s

[rambutan2] 25/9/2006 10:22

groundbreaking permission...

YM BioScience receives clearance to import nimotuzumab for clinical research
in the US

- Clearance will allow YM to submit an Investigational New Drug (IND)
application to the FDA -

MISSISSAUGA, ON, Sept. 25 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,
AIM:YMBA), a company engaged in the acquisition, development and
commercialization of oncology and acute care products, today announced that
the Office of Foreign Assets Control (OFAC) of the US Treasury Department has
approved a license that allows YM BioSciences' wholly-owned U.S. subsidiary to
import nimotuzumab into the United States for the purpose of clinical trials
in pediatric patients with pontine glioma. Nimotuzumab is a monoclonal
antibody that targets the Epidermal Growth Factor Receptor (known as EGFR) and
was developed at the Center for Molecular Immunology affiliated with the
University of Havana.
As a result of the OFAC license, YM BioSciences plans to submit an IND to
the FDA to allow the investigation of nimotuzumab for the treatment of
children with intrinsic diffuse pontine glioma. Upon FDA granting permission
for the IND to proceed nimotuzumab, to the knowledge of the company, would be
the first anti-cancer drug from Cuba to be used in clinical trials in the US.
"Diffuse pontine glioma is an inoperable malignant brain cancer that only
affects children and, furthermore, it is a treatment resistant tumor so that
children currently suffering from it have few treatment options," said David
Allan, Chairman and CEO of YM BioSciences. "With this license from OFAC, we
propose to submit an IND to the FDA to investigate nimotuzumab, thus
potentially allowing US children access to the drug through a controlled
clinical trial setting while collecting efficacy and safety data. Nimotuzumab
has been available to children in other countries through their participation
in clinical trials since 2004. At present median survival following diagnosis
and treatment with radiation or chemoradiation is approximately 8.5 months,
and median survival after recurrence following treatment is approximately
three months."
Preliminary data from a Phase II nimotuzumab monotherapy study in Germany
in pediatric high-grade glioma were presented at SIOP in 2005 and at ASCO in
2006. Data from this study formed the basis for a currently ongoing Phase III
trial, combining nimotuzumab with radiation, in Europe through YM BioSciences'
licensee OncoScience AG. Final results of that Phase II trial were presented
at the 38th Congress of the International Society of Paediatric Oncology,
Geneva, Switzerland, September 18, 2006.
The OFAC license permitting the import of nimotuzumab is an important
first step towards preparing to initiate US clinical trials, and provided that
the FDA concurs with the design a trial in diffuse intrinsic pontine glioma
will be undertaken in numerous US and Canadian hospitals with the principal
investigational site being the Hospital for Sick Children in Toronto, Canada.
The current OFAC license allows the import of nimotuzumab for use in clinical
trials only. The commercialization of the drug would require an additional
license from OFAC.
Nimotuzumab, which is currently approved in India, China, Argentina, and
Columbia as well as Cuba, was recently licensed by YM to Daiichi
Pharmaceutical Co. for the Japanese market. In Europe and Canada, the drug is
in numerous clinical trials including non-small cell lung cancer, pediatric
glioma and refractory solid tumours (principally colorectal). That latter
study evaluated nimotuzumab as monotherapy. The study was conducted at The
Princess Margaret Hospital in Canada in 2006 and demonstrated significant
clinical benefit in this highly refractory patient population. Data from this
study will be submitted to upcoming medical meetings in 2007.

[rambutan2] 06/8/2006 12:21

re previous post...

YM Biosciences Licenses Monoclonal Antibody, Nimotuzumab, to Daiichi
Pharmaceutical for Japan

MISSISSAUGA, ON, July 31 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,
AIM:YMBA), a company engaged in the acquisition, development and
commercialization of oncology and acute care products, today announced that
its majority owned subsidiary, CIMYM BioSciences Inc. (CIMYM), has licensed
development and marketing rights in Japan for its anti-EGFR humanized
antibody, nimotuzumab, to Daiichi Pharmaceutical Co., Ltd. (a wholly owned
subsidiary of DAIICHI SANKYO COMPANY, LIMITED, one of Japan's largest
pharmaceutical companies).
Under the agreement, CIMYM will receive an up-front payment of
US$14.5 million and significant milestone payments at certain stages of
development for each of a number of indications as well as payments based on
supply of nimotuzumab and sales performance in the territory. Daiichi will
develop nimotuzumab for the Japanese market in several cancer indications.
"This is an exceptional agreement that provides nimotuzumab with the
prospect of accessing the second largest pharmaceutical market in the world.
The license will result in a substantial broadening of the development and
commercialization efforts directed to our anti-cancer antibody," said David
Allan, Chairman & CEO of YM BioSciences.
In July 2006, nimotuzumab was approved in India for the treatment of head
and neck cancer. Nimotuzumab is currently in a Phase IIl trial in Europe in
combination with radiation for the treatment of pediatric pontine glioma. A
trial in North America in pediatric pontine glioma is also currently in
design. Nimotuzumab is being variously developed in non-small cell lung
cancer, pediatric glioma and pancreatic cancer in Canada and Europe and YM is
preparing to pursue further clinical development of the drug in adult glioma
and colorectal cancer as well as a number of other indications. YM's licensor,
CIMAB SA, and its parent, the Center for Molecular Immunology, are conducting
trials with nimotuzumab in glioma, breast, esophageal, uterine cervix,
prostate and head and neck cancers. In the pediatric and adult trials in
Europe, the head & neck trial in India, and in trials in Canada and elsewhere,
the debilitating side effects of severe rash, diarrhea, conjunctivitis and
hypomagnesemia, evident in some or all of the other products in development
targeting the tyrosine kinase pathway, were not observed.

About DAIICHI SANKYO COMPANY, LIMITED.
DAIICHI SANKYO COMPANY, LIMITED was established on September 28, 2005 as
the joint holding company of two major Japanese pharmaceutical companies -
Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd. DAIICHI SANKYO aims to
become a Global Pharma Innovator, continuously generating innovative drugs and
services and maximizing its corporate value. Sankyo and Daiichi Pharmaceutical
have experience developing and marketing one of the world's leading oncology
products, Irrinotecan Hcl, in Japan and have a broad range of major drug
products in that market, including the antihypertensive Olmetec(R) (olmesartan
medoxomil) and the synthetic antibacterial agent Cravit(R) (levofloxacin) and
are strongly promoting drug information provision activities. In addition to
cancer, both companies are established in the field of cardiovascular disease
and have used their cumulative knowledge and expertise as a foundation for
developing an abundant product lineup and R&D pipeline.
For further details, please refer to the company Web site, at


Conference Call Notice
YM BioSciences will be holding a conference call for Analysts and
Portfolio Managers to discuss the licensing agreement on Monday, July 31, 2006
from 11:00am EDT. To participate in the conference call, dial 416-644-3415 or
1-866-250-4910. The conference call will also be audio cast live and archived
for 90 days at www.ymbiosciences.com.

[rambutan2] 06/8/2006 03:13

10:20 AM ET
Business Morning with Jim O'Connell
YM Wins Japanese Licensing Deal
David Allan, chairman and CEO, YM Biosciences

Duration: 7 m 6 s

[rambutan2] 21/7/2006 12:49

all still ticking along (ignoring share price fluctuations) nicely over last couple of months...

[_dan_] 25/6/2006 00:10

Cuba has developed the first monoclonal antibody from transgenic plants -- dubbed a 'plantibody' -- used in making a human vaccine.

The antibody, CB-Hep.1, is from an 'ancestor' of the tobacco plant. Scientists billed it as a breakthrough.

It replaces an antibody obtained from mice in Cuba's manufacturing of the hepatitis B vaccine, an AFP report quoted researchers as saying in Havana.

Carlos Borroto, deputy director at Cuba's Biotechnology and Genetic Engineering Center (CIGB), said the plantibody had won approval from Cuba's medication quality control agency, part of the public health ministry.

CB-Hep.1 is the first plantibody authorised anywhere in the world for manufacturing a vaccine. It is just the second approved for human use, after one approved in the US for treating tooth decay.

The plantibody won approval back on April 11 and is already being used in manufacturing the vaccine, though Cuba only made the announcement yesterday.

According to the report, Borroto said since the breakthrough was achieved, '145 million doses have been exploited and not a single problem in their use has been reported".

Antibodies used to date in making therapeutic vaccines for humans have been obtained from fermentation of mammalian cells, a time-consuming, costly method that generates very small quantities.

Using plantibodies in contrast is hailed as a breakthrough in dramatically reducing costs but most importantly in boosting the yield of antibodies, which makes it easier for vaccines to be produced.

Barroto said Cuba had several plantibody projects in advanced stages, including one to be used as a cancer treatment, from the same plant.

'Approval of the first CIGB plantibody clears the way for many potential uses of this alternative in manufacturing molecules important in the fight against devastating diseases,' Barroto said.

He said the 'ancestral' tobacco plant in question was a noncommercial variety, with thicker leaves, grown in an inert environment, without soil, which helps ensure biosecurity.

'A number of major international companies are looking for a partnership with us,' Barroto addes, without naming the companies

[rambutan2] 17/5/2006 01:44

rather too many probably!

but seriously, approx 30 main holdings and i tend to hold for many months/years as i await a rerating - i'm not good at trading.

[praipus] 16/5/2006 13:54

rambutan2, pardon me for asking but how many holdings do you have and how long do you hold for on average?

[rambutan2] 15/5/2006 10:40

MISSISSAUGA, ON, May 12 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,

AIM:YMBA), the cancer product development company, today reported operational

and financial results for the third quarter of fiscal 2006, ended March 31,

2006.

"With multiple clinical trials ongoing for our three late-stage products,

tesmilifene, nimotuzumab, and AeroLEF(TM), it is an exciting, active time at

YM with numerous milestone events ahead. For tesmilifene, several early

analyses of data from the ongoing pivotal trial will precede the conclusion of

the trial which is expected in the first half of 2007. If any of these early

analyses produces suitably positive results we will be in position to submit

our lead drug, which received fast track designation during the quarter, for

FDA approval," said David Allan, Chairman and CEO of YM BioSciences. "The

acquisition of Eximias will enable YM to transform into a more fully

integrated cancer company with the capability and flexibility to bring our

well-advanced products to market. It will ensure YM is well positioned for the

prospect of the success of tesmilifene without having to rely solely on a

partner for manufacturing and marketing."


Highlights:

- Received FDA Fast Track designation for tesmilifene in advanced breast

cancer.

- Entered into a collaborative agreement with Sanofi-Aventis to

investigate the effect of combining tesmilifene and Taxotere(R)

(docetaxel) for the treatment of women with rapidly progressing

metastatic breast cancer. Enrolment is targeted for completion in

calendar Q3, 2006.

- Enrolled the first patient in YM's multi-center Phase I/II Non-Small-

Cell Lung Cancer (NSCLC) trial of nimotuzumab, our humanized anti-EGFr

monoclonal antibody. YM expects to complete recruitment for the NSCLC

trial in late 2007 or early 2008.

- YM BioSciences partner, Oncoscience AG, commenced patient treatment in

a Phase III trial in Germany with nimotuzumab. Oncoscience expects the

trial should be completed in the first half of 2007.

- Initiated a Phase IIb trial for AeroLEF(TM). The trial is expected to

report preliminary results within the first half of calendar 2006.

- Raised US $40 million through a "registered direct" offering of common

shares.

- Announced its acquisition of Eximias Pharmaceutical Corporation.



Financial Results

Total revenue for the quarter ended March 31, 2006 was $684,456 compared

to $203,108 for the same period last year. Total revenue for the first nine

months of the 2006 fiscal year was $1,476,693 compared to $1,193,106 for the

corresponding nine-month period last year. Revenue consisted of revenue

generated from out-licensing agreements and interest income.

Total expenditures for the quarter ended March 31, 2006 were $6,558,668

compared to $4,483,146 for the same period last year. Total expenditures for

the first nine months of the 2006 fiscal year were $18,827,093 compared to

$10,443,903 for the first nine months of the corresponding period last year.

General and Administrative expenses for the third quarter were $1,876,575

and for the first nine months were $4,558,347 compared to $1,486,357 and

$4,003,648, respectively, for the same periods in the prior year. Licensing

and Product Development expenses for the third quarter were $4,682,093 and for

the first nine months were $14,268,746 compared to $2,996,789 and $6,440,255,

respectively, for the same periods in the prior year. Expenditure increases

were due primarily to the rapid progression of the tesmilifene Phase III

clinical trial and the inclusion of costs associated with the development of

the AeroLEF(TM) technology.

Net loss for the third quarter was $5,772,479 and for the year to date

was $17,232,617 compared to $4,277,762 and $9,376,625 respectively for the

same periods last year.

As at March 31, 2006 the Company had cash and short-term deposits

totaling $63,407,634 and current liabilities of $3,686,028 compared to

$30,568,845 and $3,825,615 respectively at June 30, 2005.

[rambutan2] 27/4/2006 14:00

v good news. nimo has true megabuster potential...

MISSISSAUGA, ON, April 27 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,

AIM:YMBA), the cancer product development company, today announced that its

partner, Oncoscience AG, has commenced patient treatment for its Phase III

trial of nimotuzumab in combination with radiation in children with diffuse,

intrinsic pontine (brain stem) glioma. The first three patients were recruited

within the last week.

The trial is a single arm study in which 40 children with inoperable

pontine glioma will be treated with radiation concomitant with nimotuzumab.

The primary clinical endpoints in the trial will be progression-free survival

with median survival as secondary endpoint. Clinical sites will be located in

Germany, Italy, Belarus and Russia and it is anticipated that recruitment

could be complete within approximately 12 months after the start of patient

enrolment. Based on historical data reporting progression-free survival and

median survival for this form of cancer of approximately 5.5 months and 8.5

months respectively, Oncoscience expects the trial should be completed in the

first half of 2007.

YM BioSciences has previously announced that it and its majority owned

subsidiary, CIMYM Inc., propose to file for authorization to conduct a trial

in a similar patient population in North America. In addition YM is

undertaking the clinical development of nimotuzumab in Non-Small Cell Lung

Cancer. YM's licensor, CIMAB SA and its parent, the Center for Molecular

Immunology, are conducting trials with nimotuzumab in glioma, breast,

esophageal, uterine cervix, prostate and head and neck cancer.

[rambutan2] 20/4/2006 03:48

Biocon, which owns the rights to Nimo in India, has announced that it is seeking regulatory approval of BIOMAb EGFR (the same drug as Nimotuzumab) next month for head and neck cancer. See below. This is a positive for YM with Nimo getting approval in another country. I would imagine that Biocon will provide its trial results next month as well.



Biocon to file for approval of cancer drug

April 18, 2006
Publication : Business Standard

Biocon Biopharmaceuticals, a Biocon subsidiary which has completed the clinical trials for BIOMAb EGFR, a novel monoclonal antibody for the treatment of head and neck cancer, will file for regulatory approval in a month. The final product is likely to be launched by the end of the year.

Kiran Mazumdar-Shaw, chairman and managing director, Biocon, speaking to reporters after the inauguration of Biocon Biopharmaceuticals' facility here on Monday said that the clinical trials were conducted at Manipal Hospital in Bangalore and KMC hospitals in Mangalore and Manipal.

"It is now for the regulators to look at the data and approve it. We are in the process of compiling the data and filing it before the Drug Controller General of India (DGCI) for approval. We will be filing it next month," she added.

BIOMAb EGFR is engineered to specifically target and block the epidermal growth factor receptor (EGFR) responsible for the proliferation of cancer cells. BIOMAb EGFR will spearhead Biocon Biopharmaceuticals' foray into proprietary products for cancer therapy in India.

Biocon Biopharmaceuticals' immunotherapeutic portfolio is a comprehensive approach targeting both receptors (EGFR and HER 1) and proliferation factors (EGF and TGF) aimed at complete remission and possible cure, said Kiran Mazumdar Shaw. Cuba's CIMAB, which originally identified the BlOMAb EGFR molecule, has entered into co development agreements with firms in China and Germany, as also Biocon. "BIOMAb EGFR being developed in India is exclusively for marketing in India and South Asia. There is also a supply arrangement with CIMAB for selling it in the US market," she said. It is estimated that the incidence of new cancer cases in India is about seven lakh annually of which nearly 2.3 lakh are tobacco-related and occur in the head and neck region. In addition to head and neck cancer, monoclonal antibodies are emerging as the fastest growing segment especially in autoimmune diseases like rheumatoid arthritis.

There are about 18 monoclonal antibodies approved globally for therapeutic use with the present market size of $15 billion. This is expected to double by 2010, said Kiran Mazumdar-Shaw.

[rambutan2] 20/4/2006 03:44

YMI YM BioSciences: Color on Eximias acquisition (5.79 +0.19) -Update-

A.G. Edwards notes that on April 13 YMI announced it will acquire privately-held pharmaceutical co Eximias Pharma. Firm says that for a considerable time, YMI's mgmt team has needed to expand its internal resources to accelerate the development of its clinical pipeline while pursuing strategic business development opportunities. In one fell swoop, YMI has added a team with vast experience while strengthening its cash position. Firm believes that the acquisition of Eximias will provide YMI with additional seasoned mgmt, which should result in YMI being able to accelerate the clinical development of its pipeline candidates. In addition, firm says the acquisition of Eximias provides YMI with at least $25 mln net cash, and will provide YMI with a much-needed U.S. presence.

[rambutan2] 07/4/2006 02:50

and here is your chance to listen to the research and development day presentations...

[rambutan2] 07/4/2006 02:07

ag edwards post research day update...
YM BIOSICIENCES
UPDATED AT 08:26 by Res-YM Biosciences (YMI/5.85)(buy/speculative)YM Analyst day, ver well attended-focus was on TheresCIM. Reiterate buy rating, PO=$15. ThereaCIM-YMI's drug that may ofer advantages over Imclone's Erbitux and Amgen pantuminimab. Dr. Leaonard Saltz, internaternationally recognized expert in the develpment of new treatments for colrectal cancer and resides at Memorial-Sloan Kettering cancer Center in New York. He recently joined YM's advisory board due to his optimism for TheraCim. We have seen clinical efficacy for TheraCIM in brain cancer, without the rash or diarrea. He stated that if efficacy can be shown to be equal to or better than Erbitux without the rash(which has not been shown)then in his opinion TheraCIM could replace Erbitux use. YM has plans to test ThereCIM in colorectal cancer, most likely in Europe, using a Phase 2 design that Erbitux was studied to see if the same response rate is achieved. This could be completed with data available in H1:07E.

[rambutan2] 05/4/2006 03:22

and it's research and development day for ym today...

Harvard Club of NYC
The Harvard Hall
27 West 44th Street
New York, NY
11:30 AM - 3:00 PM

Lunch will be available starting at 11AM.
Late afternoon Drinks available starting at 3:30 PM.

Panel Members and presenters:
- David Allan, Chairman & CEO, YM BioSciences
- Dr. Leonard Bruce Saltz, Memorial Sloan-Kettering Cancer Center
- Dr. Paul M. Keane, Director, Medical Affairs, YM BioSciences
- Dr. Diana Pliura, CEO, Delex Therapeutics
- Dr. Mark Vincent, Director, Investigational Oncology, YM BioSciences
- Dr. Peter John Ferguson, Cancer Research Laboratories - VRL London Regional Cancer Program - London Health Sciences Centre
- Dr. Elias Georges, Institute of Parasitology, McGill University
- Dr. Jin-Ming Yuan, Cancer Institute of New Jersey

Description
11:30 am Introduction
David Allan
Chairman and CEO
YM BioSciences Inc.
11:45 a.m Development of Multidrug Resistance (MDR) and Strategies to Circumvent It
Jin-Ming Yang, MD, PhD
Associate Professor
Robert Wood Johnson Medical School, UMDNJ, New Jersey
12:05 p.m Tesmilifene : Mode of Action
Mark Vincent, MD, MRCP, FRCPC
Director, Investigational Oncology, YM BioSciences Inc.
Associate Professor, Dept. of Oncology, University of Western Ontario
Staff Medical Oncologist, London Regional Cancer Program
12:45 p.m. Q&A & Break
1:30 p.m. Experiences of Important Therapeutic Advances with Epidermal Growth Factor Receptor Blockade
Leonard Saltz, MD
Memorial Sloan-Kettering Cancer Center
Memorial Hospital for Cancer and Allied Diseases
Professor of Medicine, Weill College of Medicine, Cornell University
1:55 p.m. Nimotuzumab
Paul Keane, MD, FRCPC, FACP, FRC Path
Director, Medical Affairs
YM BioSciences Inc.
2:30 p.m. AeroLEF
Diana Pliura, PhD
President and CEO
DELEX Therapeutics Inc., a subsidiary of YM BioSciences Inc.
2:50 p.m. Closing Remarks followed by Q&A

[rambutan2] 05/4/2006 03:19

up on other side of pond yesterday due to...

YMI YM BioSciences initiated with a Buy and a $15 price target at AG Edwards (5.69 )

Key points:

1. $15 valuation based strictly on 2010 revenue estimate of approximately $160 million in sales for tesmilifene on $465 million on sales with a price of about $9600 per patient per year.

2. They note that TELK has a market cap of $1 billion although "Telik does not have positive data from a phase III trial (where YM does) nor does it have a robust pipeline."

3. They add only $100 million for the value of the non-tesmilifene pipeline (only nimo and AeroLef); nevertheless they think YMI will have a 2007 value of roughly $800 million

4. They did not include the propargylamines or Norelin in their valuation calculation.

[rambutan2] 29/3/2006 03:00

the next step for nimo...

YM BioSciences' partner, Oncoscience AG, cleared for Phase III trial in

Germanywith nimotuzumab


- Phase II results presented at the 27th Annual German Cancer

Conference -


MISSISSAUGA, ON, March 28 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,

AIM:YMBA), the cancer product development company, today announced that its

partner, Oncoscience AG, has been cleared by the German regulatory authority

for biological products, the Paul Ehrlich Institute, to initiate a Phase III

trial of nimotuzumab in combination with radiation in children with inoperable

pontine (brain stem) glioma. The clinical trial was also reviewed with the

EMEA and is designed as a prospectively registrable study on the basis of a

single arm trial because of the absence of treatment options for children

suffering from pontine glioma. It is anticipated that marketing authorization

subsequent to a successful trial would be sought under the EMEA centralized

procedure.

[rambutan2] 22/3/2006 01:10

still over $6.

[rambutan2] 15/3/2006 03:00

steamed through $6 to close up 7% at $6.19 on amex.

[rambutan2] 14/3/2006 11:45

stateside yesterday...

YMI YM BioSciences target increase details (5.74 +0.08) -Update-

As mentioned at 13:17, Ragen Mackenzie raised their tgt on YMI to $10 from $6. Firm believes that there is further upside to the stock price if positive results are demonstrated in the first interim analysis of tesmilifene, which they expect in mid-2006. If tesmilifene can demonstrate a 50% or better improvement in survival at the first interim analysis, the firm says the co will be able to stop the trial to file for FDA approval, as per a Special Protocol Assessment agreement with the FDA. With positive results from this trial, firm expects that mgmt will focus its efforts on partnering tesmilifene with a larger pharma co that could manage both the manufacturing and marketing of the drug.


and germany yesterday...

Germany up to 5.39 EURO

There is a $35 Target in an Newspaper.

More then 80k Shares are trade.
At a normal day we 1 to 10k.

https://www.cortalconsors.de/euroWebDe/-;jsessionid=GWyFgLYQMQYh92p9QJtQGY7YvN29pwVqKVjTSXdh0JNRwWVvCJdv!-764141594?%24event=search&pattern=ymi&%24part=Home.index.security-search

[suesean1] 10/3/2006 02:39

rambutan2

Congrats on this, well researched. Take a few mins and have a look at epic (alvr) on nasdaq.